- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01995552
IdeNtifying High riSk Patients Post Myocardial Infarction With REduced Left Ventricular Function Using External Loop Recorders (INSPIRE-ELR Study) (INSPIRE-ELR)
August 19, 2019 updated by: Medtronic BRC
The purpose of the INSPIRE-ELR study is to characterize arrhythmias in post MI low EF (≤35%) patients in the acute phase (at discharge from hospital after index MI) and chronic phase (at 8-10 weeks after index MI) and to correlate with patients at high risk of all-cause mortality or sudden cardiac death (SCD) at 1 year.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The study is a prospective, multi-center, interventional, non-randomized study enrolling post MI low left ventricular ejection fraction (LVEF ≤35%) patients prior to or at discharge from the hospital after index MI as defined in the inclusion criteria.
Prior to initiating any study specific procedures, patients needs to provide his/her consent by signing and dating an informed consent form.
Inclusion/Exclusion criteria will be evaluated and the patients' medical history and baseline information will be collected.
Seven days ELR monitoring will be done at discharge and at chronic phase after index MI.
At 6 and 9 months telephone follow-up will be done to evaluate the health status, if there will be no in-office visit planned.
At 12 months there will be a scheduled in-office visit conducted to collect the health status.
All the patients will be followed-up by telephone (health status) at study end (when the last patient completed the 12 month follow-up)
Study Type
Interventional
Enrollment (Actual)
250
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Haryana
-
Gurgaon, Haryana, India, 122001
- Medanta - The Medicity
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Patients must meet all of the below criteria to be eligible for the study:
- Patients must provide written informed consent/data release consent to
- participate in the study.
- Acute Myocardial Infarction (STEMI or non-STEMI) documented within 10 days of onset, matching one of the following criteria:
- Acute ST segment elevation greater than or equal to 0.1 mv on ECG in 2 or more leads or new LBBB, with symptoms of ischemia
- In all other situations, including non ST segment elevation MI, at least one cardiac biomarker value [preferably cardiac troponin (cTn)] above the 99th percentile of a normal reference population (upper reference limit (URL)) AND with at least one of the following (1) new or presumed new ST-T changes (2) Symptoms or signs of Ischemia (3) Development of pathological Q waves in the ECG (4) Identification of an intracoronary thrombus by angiography
- LVEF less than or equal to 35 percent as measured by echocardiography Simpsons method, biplane one day before or on the day of hospital discharge
Exclusion Criteria
- Patients who cannot be discharged from the hospital within14 days after index Myocardial Infarction event
- Age less than 18 years
- Psychologically incapacitated
- Patient is pregnant, or is expecting to become pregnant during the course of the trial per Investigator discretion.
- Patients contraindicated for NUVANT system
- Comorbidities likely to limit survival to less than the minimal study duration (12 months)
- Participation in an investigational study with known or suspected cardiac effect expected to confound the results of this study (e.g. stem cell trials, stent trials, cardiac intervention trials, drug trials)
- Patients with an existing pacemaker or ICD implanted.
- Patients that are dialysis dependent at discharge
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: External Loop Recorder
This is a non-randomized study.
All the patients will be enrolled will received the ELR system.
|
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The Primary Objective of the Study is to Assess Percent of Participants With Clinically Significant Arrhythmias on ELR Post MI
Time Frame: 7 days post discharge
|
Post MI mortality is higher in India than in the US and Western Europe.
The hypothesis of the INSPIRE-ELR study was that occurrence of arrhythmias in the acute phase of MI will identify patients at highest risk and we evaluated the percentage clinical signification arrhythmias captured through the ELR post MI in acute phase
|
7 days post discharge
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Determine Percentage of Patients With Non-lethal Arrhythmias on ELR Post MI Have a Higher Risk of All-cause Mortality at 1 Year
Time Frame: 12 Months
|
Analysis included all patients that completed the acute monitoring period.
Based on the arrhythmias detected during the acute ELR monitoring period, patients were classified as "with arrhythmia" when during the ELR monitoring period there is any episode of ELR monitored events listed.
All other patients are classified "without arrhythmia".
Mortality rates after the monitoring period was estimated for both groups.
|
12 Months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2014
Primary Completion (Actual)
February 20, 2016
Study Completion (Actual)
April 1, 2017
Study Registration Dates
First Submitted
November 21, 2013
First Submitted That Met QC Criteria
November 25, 2013
First Posted (Estimate)
November 26, 2013
Study Record Updates
Last Update Posted (Actual)
August 20, 2019
Last Update Submitted That Met QC Criteria
August 19, 2019
Last Verified
August 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- Version 3.0 , 22 Apr 2015
- REF/2013/10/005823 (Other Identifier: Clinical Trial Registry - India)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Post MI Left Ventricular Dysfunction
-
PfizerCompletedLeft Ventricular Dysfunction Post Myocardial Infarction
-
Berlin Heart, IncUnknownSevere Isolated Left Ventricular Dysfunction | Severe Biventricular Dysfunction
-
Lawson Health Research InstituteMedtronicTerminatedHeart Failure, Left Ventricular DysfunctionCanada
-
Berlin Heals GmbHRecruitingSystolic Left Ventricular DysfunctionSerbia, Bosnia and Herzegovina
-
Berlin Heals GmbHRecruitingSystolic Left Ventricular DysfunctionSwitzerland, Croatia, Germany, Spain, Serbia, Bosnia and Herzegovina, Bulgaria, Greece, North Macedonia, Poland, Czechia
-
M.D. Anderson Cancer CenterCompletedHeart Failure | Cancer Treatment Induced Left Ventricular DysfunctionUnited States
-
AstraZenecaCompletedLeft Ventricle FunctionSweden
-
National Defense Medical Center, TaiwanRecruitingLeft Ventricular Systolic Dysfunction (Disorder)Taiwan
-
University of LeedsCompletedLeft Ventricular Function Systolic DysfunctionUnited Kingdom
-
University Hospital DubravaUnknownRight Ventricular Dysfunction | Left Ventricular Dysfunction | Biventricular FailureCroatia
Clinical Trials on External Loop Recorder
-
National University of Ireland, Galway, IrelandHealth Research Board, IrelandCompletedAtrial Fibrillation and FlutterIreland
-
TriHealth Inc.MedtronicUnknown
-
Rigshospitalet, DenmarkActelionRecruitingArrhythmias, Cardiac | Pulmonary Hypertension | Heart Rate Variability | Risk AssessmentDenmark
-
Leonardo Calò, MDNot yet recruiting
-
Leif ThuesenRecruitingChronic Total Coronary OcclusionDenmark
-
Fundación Instituto de Estudios de Ciencias de...Instituto de Salud Carlos III; Spanish Society of Cardiology; Sanidad de Castilla...Active, not recruitingMyocardial Infarction | Death, Sudden | Ventricular Tachycardia | Implantable Defibrillator User | Myocardial DysfunctionSpain
-
Canadian Institutes of Health Research (CIHR)Vanderbilt UniversityCompletedHeart Block | Syncope | Conduction Disorder of the HeartUnited Kingdom, Canada, United States, Malaysia, Japan
-
Barts & The London NHS TrustCompleted
-
University of PennsylvaniaMedtronicCompletedAtrial FibrillationUnited States
-
Seoul National University HospitalSamsung Medical Center; Asan Medical Center; Seoul National University Bundang... and other collaboratorsActive, not recruitingAtrial Fibrillation, PersistentKorea, Republic of